{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:17:10Z","timestamp":1791573430956,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1646-4","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T05:34:59Z","timestamp":1532669699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Stanley B.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Hala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiao C.","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad I.","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Palaparthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Lea","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"1646_CR1","volume-title":"Remicade (infliximab) summary of product characteristics. London: EMA","author":"European Medicines Agency (EMA)","year":"2017","unstructured":"European Medicines Agency (EMA). Remicade (infliximab) summary of product characteristics. London: EMA; 2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf\n                    \n                  . Accessed 14 Aug 2017."},{"key":"1646_CR2","unstructured":"Janssen Biotech Inc. Remicade (infliximab) US prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2017. \n                     https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761072s000lbl.pdf\n                    \n                  . Accessed 14 Aug 2017."},{"key":"1646_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343:1594\u2013602.","journal-title":"N Engl J Med"},{"key":"1646_CR4","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St Clair","year":"2004","unstructured":"St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432\u201343.","journal-title":"Arthritis Rheum"},{"key":"1646_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1345580","volume":"5","author":"Z Kalo","year":"2017","unstructured":"Kalo Z, Voko Z, Ostor A, Clifton-Brown E, Vasilescu R, Battersby A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5:1345580.","journal-title":"J Mark Access Health Policy"},{"key":"1646_CR6","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1080\/03007995.2016.1227775","volume":"32","author":"M Cifaldi","year":"2016","unstructured":"Cifaldi M, Renaud J, Ganguli A, Halpern MT. Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009. Curr Med Res Opin. 2016;32:2029\u201337.","journal-title":"Curr Med Res Opin"},{"key":"1646_CR7","unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA). Guideline on similar biological medicinal products. London: EMA; 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf\n                    \n                  . Accessed 14 Aug 2017."},{"key":"1646_CR8","volume-title":"Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. Silver Spring, MD: FDA","author":"US Food and Drug Administration (FDA)","year":"2015","unstructured":"US Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. Silver Spring, MD: FDA; 2015. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf\n                    \n                  . Accessed 14 Aug 2017."},{"key":"1646_CR9","unstructured":"IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. Parsippany, NJ: IMS Health and the IMS Institute for Healthcare Informatics; March 2016. \n                    https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf\n                    \n                  . Accessed 21 Aug 2017."},{"key":"1646_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","volume":"32","author":"A Jha","year":"2015","unstructured":"Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima\u00ae) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742\u201356.","journal-title":"Adv Ther"},{"key":"1646_CR11","first-page":"s331","volume":"21(16 Suppl)","author":"SC Singh","year":"2015","unstructured":"Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21(16 Suppl):s331\u201340.","journal-title":"Am J Manag Care"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304\u201316.","journal-title":"Lancet"},{"key":"1646_CR13","unstructured":"Pfizer Inc. Ixifi (infliximab-qbtx) US prescribing information. Pfizer Inc. 2017. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761072s000lbl.pdf\n                    \n                  . Accessed 2 July 2018."},{"key":"1646_CR14","unstructured":"European Medicines Agency. Zessly (infliximab) summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004647\/WC500249647.pdf\n                    \n                  . Accessed 2 July 2018."},{"key":"1646_CR15","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1007\/s12325-016-0403-9","volume":"33","author":"M Derzi","year":"2016","unstructured":"Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, et al. Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade\u00ae (infliximab). Adv Ther. 2016;33:1964\u201382.","journal-title":"Adv Ther"},{"key":"1646_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/1744666X.2018.1446829","volume":"14","author":"R Palaparthy","year":"2018","unstructured":"Palaparthy R, Udata C, Hua SY, Yin D, Cai CH, Salts S, et al. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179\/GP1111 with Remicade\u00ae (infliximab) in healthy subjects (REFLECTIONS B537-01). Expert Rev Clin Immunol. 2018;14:329\u201336.","journal-title":"Expert Rev Clin Immunol"},{"key":"1646_CR17","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1646_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498\u2013502.","journal-title":"Arthritis Rheum"},{"key":"1646_CR19","unstructured":"ClinicalTrials.gov. A study of PF-06438179 (infliximab-Pfizer) and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis (REFLECTIONS B537\u201302). Registered on 21 Aug 2014. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02222493\n                    \n                  . Accessed 14 Aug 2017."},{"key":"1646_CR20","volume-title":"Guidance for industry. Rheumatoid arthritis: developing drug products for treatment. Rockville, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER)","author":"US Food and Drug Administration (FDA)","year":"2013","unstructured":"US Food and Drug Administration (FDA). Guidance for industry. Rheumatoid arthritis: developing drug products for treatment. Rockville, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER); 2013. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm354468.pdf\n                    \n                  . Accessed 22 Aug 2017."},{"key":"1646_CR21","first-page":"37","volume":"33","author":"T Abe","year":"2006","unstructured":"Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol. 2006;33:37\u201344.","journal-title":"J Rheumatol"},{"key":"1646_CR22","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet. 1999;354:1932\u20139.","journal-title":"Lancet"},{"key":"1646_CR23","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096\u2013103.","journal-title":"Ann Rheum Dis"},{"key":"1646_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/art.21734","volume":"54","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075\u201386.","journal-title":"Arthritis Rheum"},{"key":"1646_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1479-8077.2006.00186.x","volume":"9","author":"F-C Zhang","year":"2006","unstructured":"Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol. 2006;9:127\u201330.","journal-title":"APLAR J Rheumatol"},{"key":"1646_CR26","first-page":"181","volume-title":"Biosimilar clinical development: scientific considerations and new methodologies","author":"SY Hua","year":"2017","unstructured":"Hua SY, Xu S, Barker KB, Liao SM, Li S. Bayesian methods to assess bioequivalence and biosimilarity with case studies. In: Barker KB, Menon SM, D\u2019 Agostino RB, Xu S, Jin B, editors. Biosimilar clinical development: scientific considerations and new methodologies. Boca Raton, FL: CRC Press; 2017. p. 181\u201398."},{"key":"1646_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1756-185X.12202","volume":"17","author":"R Alten","year":"2014","unstructured":"Alten R, van den Bosch F. Dose optimization of infliximab in patients with rheumatoid arthritis. Int J Rheum Dis. 2014;17:5\u201318.","journal-title":"Int J Rheum Dis"},{"key":"1646_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/rheumatology\/kel326","volume":"46","author":"R Ariza-Ariza","year":"2007","unstructured":"Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J. Dose escalation of the anti-TNF-\u03b1 agents in patients with rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2007;46:529\u201332.","journal-title":"Rheumatology (Oxford)"},{"key":"1646_CR29","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1185\/03007990802229548","volume":"24","author":"E Wu","year":"2008","unstructured":"Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24:2229\u201340.","journal-title":"Curr Med Res Opin"},{"key":"1646_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","volume":"16","author":"H Lee","year":"2014","unstructured":"Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16:22\u20136.","journal-title":"AAPS J"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1646-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1646-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1646-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T14:42:31Z","timestamp":1569249751000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1646-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1646-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"29 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in compliance with the provisions of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines, and it was reviewed and approved by an institutional review board or independent ethics committee(s) at each of the participating investigational sites. All patients provided informed consent prior to undergoing any screening procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SBC has received consulting fees from Amgen, Boehringer-Ingelheim, Coherus, Merck, Pfizer, and Sandoz and has received research grants from Amgen, Boehringer-Ingelheim, Coherus, Merck, and Pfizer. RA has received honoraria and research grants from Pfizer. HK has received consulting fees, speaking fees, and\/or honoraria from AbbVie GK, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Novartis Pharma K.K., Pfizer Japan Inc., and Sanofi K.K. and has received research grants from AbbVie GK, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical Co. Ltd. SCR has received research grants and consulting fees, speaking fees, and\/or honoraria from Pfizer Inc. TH has no competing interests to disclose. KS and SS are employees of Hexal AG, a Sandoz company. MIR, RP, and KLS are full-time employees of and declare having stock holdings and\/or stock options from Pfizer Inc. SYH and CI were employees of and had stock holdings and\/or stock options from Pfizer Inc. at the time of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"155"}}